Matrix metalloproteinases 2, 3, 13 and their type 2 tissue inhibitor in tumors and plasma of patients with colorectal cancer.
Enzyme immunoassay studies revealed increased content of matrix metalloproteinases 2, 3 and 13 in tumors compared to the adjacent histologically unchanged mucosa in 70-90% patients with colorectal cancer, while the increase in the content of type 2 metalloproteinase tissue inhibitor did not reach the level of statistic significance. Plasma concentrations of these proteins did not correlate with the corresponding values in the tumors and did not surpass the normal levels, while their decrease after removal of the primary tumor was observed only in patients with initially high levels of this parameter.
Gershtein
E S
ES
N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow. esgershtein@gmail.com
Korotkova
E A
EA
Prorokov
V V
VV
Kushlinsky
N E
NE
D000328:Adult; D000368:Aged; D015179:Colorectal Neoplasms / Q000097:blood* / Q000378:metabolism / Q000601:surgery; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007413:Intestinal Mucosa / Q000378:metabolism; D008297:Male; D053509:Matrix Metalloproteinase 13 / Q000097:blood*; D020778:Matrix Metalloproteinase 2 / Q000097:blood*; D019278:Matrix Metalloproteinase 3 / Q000097:blood*; D008875:Middle Aged; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000097:blood*
D019716:Tissue Inhibitor of Metalloproteinase-2; D053509:Matrix Metalloproteinase 13; D019278:Matrix Metalloproteinase 3; D020778:Matrix Metalloproteinase 2